Tel:
Fax:
Email:
Creative Biolabs
Product

NeuroMab™ Anti-ApoC3 BBB Shuttle Antibody,Clone NR1740P

[CAT#: NRZP-1022-ZP3507]

Host Species:
Human
Species Reactivity:
Human; Cynomolgus Monkey
Applications:
WB; ELISA; Inhib; In Vitro; In Vivo; Antagonist

Datasheet MSDS Request COA

Certificate of Analysis Lookup
To download a Certificate of Analysis, please enter a lot number in the search box below. Note: Certificate of Analysis not available for kit components.
Lot Number

Inquiry

SPECIFIC INQUIRY

inquiry
Size:
Conjugation:
Endotoxin:
Purity:
Engineering:
Product Overview

Description

Brain uptake of therapeutic antibodies is severely limited by their size. To achieve enhanced BBB crossing, Creative Biolabs developed a BBB shuttle antibody platform by utilizing the endogenous macromolecule transportation pathway, known as receptor-mediated transcytosis (RMT). The engineered antibody-based carrier is believed to significantly to increase the macromolecule brain entry to combat CNS diseases.
Notes: The BBB antibody is made-to order and available in a customized format. Please don't hesitate contact us for more details.

Immunogen

Human ApoC3 (huApoC3) protein

Species Reactivity

Human; Cynomolgus Monkey

Clonality

Monoclonal

Host Species

Human

Isotype

IgG

Clone Number

NR1740P

Applications

WB; ELISA; Inhib; In Vitro; In Vivo; Antagonist

Relevant Diseases

Alzheimer's Disease
Product Properties

Storage

Store at -20°C. Do not aliquot the antibody.

Research Use Only

For research use only
Target

Target

ApoC3

Official Name

ApoC3

Full Name

Apolipoprotein C-III

Alternative Names

APOC3; APOCIII; HALP2; apolipoprotein C3
Product Pictures
Inhib

Figure 1 shows that the 5E5VH5_VL8 antibody attenuates the ability of ApoC3 to inhibit the uptake of very low density lipoprotein (VLDL) by HepG2 cells.

Inhib

Figure 2 shows the pharmacokinetics and pharmacodynamics of two anti-ApoC3 antibodies, 5E5 and 5E5VH5_VL8, and an anti-egg lysosomal human IgG1 antibody (HyHe15) in the AAV8-human ApoC3 mouse model.

Test antibodies were administered intravenously to mice expressing transgenic human ApoC3. Measure human IgG1 serum levels at various times after injection and plot absolute or relative levels compared to time 0.

Inhib

Figure 3 shows the pharmacokinetics and pharmacodynamics of two anti-ApoC3 antibodies 5E5 and 5E5VH5_VL8 and an anti-egg lysosomal human IgG1 antibody (HyHe15) in the AAV8-human ApoC3 mouse model.

Test antibodies were administered intravenously to mice expressing transgenic human ApoC3. Serum levels of human ApoC3 were measured at various times after injection and the absolute or relative levels compared to time 0 were plotted.

Inhib

Figure 4 shows the pharmacokinetics and pharmacodynamics of two anti-ApoC3 antibodies, 5E5 and 5E5VH5_VL8, and an anti-egg lysosomal human IgG1 antibody (HyHe15) in the AAV8-human ApoC3 mouse model.

Test antibodies were administered intravenously to mice expressing transgenic human ApoC3. Serum levels of ApoB in mice were measured at different times after injection and plotted as absolute or relative levels compared to time 0.

Inhib

Figure 5 shows that 5E5VH5_VL8 reduces fasting triglyceride levels and circulating postprandial triglyceride levels in the AAV8-human ApoC3 mouse model (n=6 per treatment group).

The plasma triglyceride levels in mice treated with 5E5VH5_VL8 or the HyHe15 antibody before and after fasting overnight.

Inhib

Figure 6 shows that 5E5VH5_VL8 reduces fasting triglyceride levels and circulating postprandial triglyceride levels in the AAV8-human ApoC3 mouse model (n=6 per treatment group).

The plasma triglyceride levels in these mice after an olive oil challenge.

Inhib

Figure 7 shows that 5E5VH5_VL8 reduces fasting triglyceride levels and circulating postprandial triglyceride levels in the AAV8-human ApoC3 mouse model (n=6 per treatment group).

The calculated area under the curve values are plotted.

Inhib

Figure 8 shows that 5E5VH5_VL8 reduces fasting and circulating postprandial triglyceride levels in the AAV8-human ApoC3 mouse model (n=6 per treatment group).

ApoC3 levels were plotted throughout antibody treatment, fasting, and olive oil challenge.

Publications

Publications (0)

gift-card

Related Products
For Research Use Only. Not For Clinical Use.
Fill out this form for a quote Inquiry Form Send Inquiry
Inquiry Basket
compare

Send inquiry